Rohan Palekar, 89bio CEO
With data to propel it into PhIII, 89bio asks market for nearly $100M to bankroll ex-Teva drug
89bio, born out of a Teva drug, is the latest to board the speed rail that takes biotechs from positive clinical data drop to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
